Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy.

Holger Thurm; Sebastian Ebel; Christina Kentenich; Alice Hemsen; Sabine Riethdorf; Cornelia Coith; Diethelm Wallwiener; Stephan Braun; Carsten Oberhoff; Fritz Jänicke; Klaus Pantel

Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy.

Standard

Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. / Thurm, Holger; Ebel, Sebastian; Kentenich, Christina; Hemsen, Alice; Riethdorf, Sabine; Coith, Cornelia; Wallwiener, Diethelm; Braun, Stephan; Oberhoff, Carsten; Jänicke, Fritz; Pantel, Klaus.

In: CLIN CANCER RES, Vol. 9, No. 7, 7, 2003, p. 2598-2604.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Thurm, H, Ebel, S, Kentenich, C, Hemsen, A, Riethdorf, S, Coith, C, Wallwiener, D, Braun, S, Oberhoff, C, Jänicke, F & Pantel, K 2003, 'Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy.', CLIN CANCER RES, vol. 9, no. 7, 7, pp. 2598-2604. <http://www.ncbi.nlm.nih.gov/pubmed/12855636?dopt=Citation>

APA

Thurm, H., Ebel, S., Kentenich, C., Hemsen, A., Riethdorf, S., Coith, C., Wallwiener, D., Braun, S., Oberhoff, C., Jänicke, F., & Pantel, K. (2003). Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. CLIN CANCER RES, 9(7), 2598-2604. [7]. http://www.ncbi.nlm.nih.gov/pubmed/12855636?dopt=Citation

Vancouver

Thurm H, Ebel S, Kentenich C, Hemsen A, Riethdorf S, Coith C et al. Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. CLIN CANCER RES. 2003;9(7):2598-2604. 7.

Bibtex

@article{2c136b77f4464f598804b371f0a49f4e,

title = "Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy.",

abstract = "Over the past 5 years, several clinical studies on a total of approximately 2500 patients have shown that the immunocytochemical detection of occult metastatic tumor cells in bone marrow (BM) at primary surgery provides important prognostic information in breast cancer (e.g., Ref 13 ). Here, we evaluated whether these cells can survive first-line chemotherapy and express epithelial cell adhesion molecule (Ep-CAM), recently suggested as promising target for immunotherapeutic interventions in breast cancer. Experimental Design: A total of 62 patients with node-negative and -positive breast cancer but without distant metastases (Tumor-Node-Metastasis stage M(0)) was treated with two or more courses of various forms of adjuvant chemotherapy (e.g., cyclophosphamide-methotrexate-5-fluorouracil, anthracyclines). After chemotherapy, BM was aspirated from the upper iliac crest and analyzed for the presence of tumor cells. A first cohort of 34 BM aspirates was enriched for tumor cells by Ficoll density gradient centrifugation, and 2-4 x 10(6) mononuclear cells were analyzed per patient. The tumor cells were detected by anticytokeratin monoclonal antibody (Mab) A45-B/B3 and double labeled with Mab 3B10 against an Ep-CAM-epitope. The subsequent 27 BM aspirates were specifically enriched for Ep-CAM(+) cells using magnetic beads coupled to Mab 3B10, and tumor cells were identified by Fab fragments of Mab A45-B/B3 directly conjugated with alkaline phosphatase.",

keywords = "Adult, Humans, Aged, Female, Middle Aged, Cohort Studies, Immunohistochemistry, Prognosis, Cell Line, Tumor, Neoplasm Metastasis, Centrifugation, Density Gradient, Cell Adhesion, Immunotherapy, Bone Marrow Cells/metabolism, Breast Neoplasms/*metabolism, Anthracyclines/therapeutic use, Antigens, Neoplasm/*biosynthesis, Cell Adhesion Molecules/*biosynthesis, *Chemotherapy, Adjuvant, Cyclophosphamide/therapeutic use, Epitopes, Fluorouracil/therapeutic use, Methotrexate/therapeutic use, Neoplasms/metabolism, Adult, Humans, Aged, Female, Middle Aged, Cohort Studies, Immunohistochemistry, Prognosis, Cell Line, Tumor, Neoplasm Metastasis, Centrifugation, Density Gradient, Cell Adhesion, Immunotherapy, Bone Marrow Cells/metabolism, Breast Neoplasms/*metabolism, Anthracyclines/therapeutic use, Antigens, Neoplasm/*biosynthesis, Cell Adhesion Molecules/*biosynthesis, *Chemotherapy, Adjuvant, Cyclophosphamide/therapeutic use, Epitopes, Fluorouracil/therapeutic use, Methotrexate/therapeutic use, Neoplasms/metabolism",

author = "Holger Thurm and Sebastian Ebel and Christina Kentenich and Alice Hemsen and Sabine Riethdorf and Cornelia Coith and Diethelm Wallwiener and Stephan Braun and Carsten Oberhoff and Fritz J{\"a}nicke and Klaus Pantel",

year = "2003",

language = "English",

volume = "9",

pages = "2598--2604",

journal = "CLIN CANCER RES",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "7",

}

RIS

TY - JOUR

T1 - Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy.

AU - Thurm, Holger

AU - Ebel, Sebastian

AU - Kentenich, Christina

AU - Hemsen, Alice

AU - Riethdorf, Sabine

AU - Coith, Cornelia

AU - Wallwiener, Diethelm

AU - Braun, Stephan

AU - Oberhoff, Carsten

AU - Jänicke, Fritz

AU - Pantel, Klaus

PY - 2003

Y1 - 2003

N2 - Over the past 5 years, several clinical studies on a total of approximately 2500 patients have shown that the immunocytochemical detection of occult metastatic tumor cells in bone marrow (BM) at primary surgery provides important prognostic information in breast cancer (e.g., Ref 13 ). Here, we evaluated whether these cells can survive first-line chemotherapy and express epithelial cell adhesion molecule (Ep-CAM), recently suggested as promising target for immunotherapeutic interventions in breast cancer. Experimental Design: A total of 62 patients with node-negative and -positive breast cancer but without distant metastases (Tumor-Node-Metastasis stage M(0)) was treated with two or more courses of various forms of adjuvant chemotherapy (e.g., cyclophosphamide-methotrexate-5-fluorouracil, anthracyclines). After chemotherapy, BM was aspirated from the upper iliac crest and analyzed for the presence of tumor cells. A first cohort of 34 BM aspirates was enriched for tumor cells by Ficoll density gradient centrifugation, and 2-4 x 10(6) mononuclear cells were analyzed per patient. The tumor cells were detected by anticytokeratin monoclonal antibody (Mab) A45-B/B3 and double labeled with Mab 3B10 against an Ep-CAM-epitope. The subsequent 27 BM aspirates were specifically enriched for Ep-CAM(+) cells using magnetic beads coupled to Mab 3B10, and tumor cells were identified by Fab fragments of Mab A45-B/B3 directly conjugated with alkaline phosphatase.

AB - Over the past 5 years, several clinical studies on a total of approximately 2500 patients have shown that the immunocytochemical detection of occult metastatic tumor cells in bone marrow (BM) at primary surgery provides important prognostic information in breast cancer (e.g., Ref 13 ). Here, we evaluated whether these cells can survive first-line chemotherapy and express epithelial cell adhesion molecule (Ep-CAM), recently suggested as promising target for immunotherapeutic interventions in breast cancer. Experimental Design: A total of 62 patients with node-negative and -positive breast cancer but without distant metastases (Tumor-Node-Metastasis stage M(0)) was treated with two or more courses of various forms of adjuvant chemotherapy (e.g., cyclophosphamide-methotrexate-5-fluorouracil, anthracyclines). After chemotherapy, BM was aspirated from the upper iliac crest and analyzed for the presence of tumor cells. A first cohort of 34 BM aspirates was enriched for tumor cells by Ficoll density gradient centrifugation, and 2-4 x 10(6) mononuclear cells were analyzed per patient. The tumor cells were detected by anticytokeratin monoclonal antibody (Mab) A45-B/B3 and double labeled with Mab 3B10 against an Ep-CAM-epitope. The subsequent 27 BM aspirates were specifically enriched for Ep-CAM(+) cells using magnetic beads coupled to Mab 3B10, and tumor cells were identified by Fab fragments of Mab A45-B/B3 directly conjugated with alkaline phosphatase.

KW - Adult

KW - Humans

KW - Aged

KW - Female

KW - Middle Aged

KW - Cohort Studies

KW - Immunohistochemistry

KW - Prognosis

KW - Cell Line, Tumor

KW - Neoplasm Metastasis

KW - Centrifugation, Density Gradient

KW - Cell Adhesion

KW - Immunotherapy

KW - Bone Marrow Cells/metabolism

KW - Breast Neoplasms/metabolism

KW - Anthracyclines/therapeutic use

KW - Antigens, Neoplasm/biosynthesis

KW - Cell Adhesion Molecules/biosynthesis

KW - Chemotherapy, Adjuvant

KW - Cyclophosphamide/therapeutic use

KW - Epitopes

KW - Fluorouracil/therapeutic use

KW - Methotrexate/therapeutic use

KW - Neoplasms/metabolism